Krystal Biotech Statistics
Share Statistics
Krystal Biotech has 28.76M shares outstanding. The number of shares has increased by 1.65% in one year.
| Shares Outstanding | 28.76M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.11% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 24.32M |
| Failed to Deliver (FTD) Shares | 1.16K |
| FTD / Avg. Volume | 0.48% |
Short Selling Information
The latest short interest is 3.70M, so 12.86% of the outstanding shares have been sold short.
| Short Interest | 3.70M |
| Short % of Shares Out | 12.86% |
| Short % of Float | 15.21% |
| Short Ratio (days to cover) | 14.69 |
Valuation Ratios
The PE ratio is 308.15 and the forward PE ratio is 32.
| PE Ratio | 308.15 |
| Forward PE | 32 |
| PS Ratio | 66.45 |
| Forward PS | null |
| PB Ratio | 4.33 |
| P/FCF Ratio | -33.49 |
| PEG Ratio | n/a |
Enterprise Valuation
Krystal Biotech Inc. has an Enterprise Value (EV) of 3.02B.
| EV / Earnings | 276.12 |
| EV / Sales | 59.54 |
| EV / EBITDA | 168.59 |
| EV / EBIT | -27.51 |
| EV / FCF | -30 |
Financial Position
The company has a current ratio of 17.76, with a Debt / Equity ratio of 0.
| Current Ratio | 17.76 |
| Quick Ratio | 17.55 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is 0.01% and return on capital (ROIC) is -11.82%.
| Return on Equity (ROE) | 0.01% |
| Return on Assets (ROA) | 0.01% |
| Return on Capital (ROIC) | -11.82% |
| Revenue Per Employee | 221.39K |
| Profits Per Employee | 47.74K |
| Employee Count | 229 |
| Asset Turnover | 0.06 |
| Inventory Turnover | 0.44 |
Taxes
| Income Tax | 1.97M |
| Effective Tax Rate | 0.15 |
Stock Price Statistics
The stock price has increased by 30.89% in the last 52 weeks. The beta is 0.82, so Krystal Biotech 's price volatility has been higher than the market average.
| Beta | 0.82 |
| 52-Week Price Change | 30.89% |
| 50-Day Moving Average | 176.73 |
| 200-Day Moving Average | 178.96 |
| Relative Strength Index (RSI) | 38.43 |
| Average Volume (20 Days) | 244.33K |
Income Statement
In the last 12 months, Krystal Biotech had revenue of 50.70M and earned 10.93M in profits. Earnings per share was 0.4.
| Revenue | 50.70M |
| Gross Profit | 47.60M |
| Operating Income | -109.73M |
| Net Income | 10.93M |
| EBITDA | 17.90M |
| EBIT | -109.73M |
| Earnings Per Share (EPS) | 0.4 |
Balance Sheet
The company has 358.33M in cash and 8.09M in debt, giving a net cash position of 350.23M.
| Cash & Cash Equivalents | 358.33M |
| Total Debt | 8.09M |
| Net Cash | 350.23M |
| Retained Earnings | -269.83M |
| Total Assets | 982.32M |
| Working Capital | 623.64M |
Cash Flow
In the last 12 months, operating cash flow was -88.80M and capital expenditures -11.80M, giving a free cash flow of -100.60M.
| Operating Cash Flow | -88.80M |
| Capital Expenditures | -11.80M |
| Free Cash Flow | -100.60M |
| FCF Per Share | -3.7 |
Margins
Gross margin is 9.39K%, with operating and profit margins of -21.64K% and 2.16K%.
| Gross Margin | 9.39K% |
| Operating Margin | -21.64K% |
| Pretax Margin | 2.54K% |
| Profit Margin | 2.16K% |
| EBITDA Margin | 35.31% |
| EBIT Margin | -216.43% |
| FCF Margin | -198.43% |
Dividends & Yields
KRYS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 0.25% |
| FCF Yield | -2.21% |
Analyst Forecast
The average price target for KRYS is $212, which is 34% higher than the current price. The consensus rating is "Buy".
| Price Target | $212 |
| Price Target Difference | 34% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
Scores
| Altman Z-Score | 29.23 |
| Piotroski F-Score | 5 |